Research update: Stanford clinical trial — enrollment open

For those following clinical research developments — Stanford's ibogaine study has opened enrollment as of this month. **Study details (publicly available):** - Investigators: Dr. Nolan Williams and team (same group behind the 2023 PTSD/TBI veterans study) - Focus: Veterans with PTSD and traumatic brain injury - Design: Open-label, single dose - Setting: Stanford University Medical Center - Protocol: Comprehensive pre-screening, cardiac monitoring, post-treatment integration support - Duration: 12-month follow-up **Why this study matters:** The 2023 pilot showed remarkable results — significant reductions in PTSD symptoms, depression, and substance use. This larger trial aims to generate the kind of Phase 2 evidence that could support FDA approval efforts. **How to find out more:** Search ClinicalTrials.gov for "ibogaine" — there are now 8 active or recruiting trials as of this writing. **For non-veterans:** There are also trials specifically for opioid use disorder at other institutions. Check ClinicalTrials.gov. This is a genuinely exciting time for ibogaine research. The stigma is lifting as the evidence base builds.